K
Kush Dhody
Publications - 9
Citations - 291
Kush Dhody is an academic researcher. The author has contributed to research in topics: Immune system & Viremia. The author has an hindex of 6, co-authored 8 publications receiving 153 citations.
Papers
More filters
Journal ArticleDOI
CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14.
Bruce K. Patterson,Harish Seethamraju,Kush Dhody,Michael J. Corley,Kazem Kazempour,Jay Lalezari,Alina P.S. Pang,Christopher Sugai,Eisa Mahyari,Edgar B. Francisco,Amruta Pise,Hallison Rodrigues,Helen L. Wu,Gabriela M. Webb,Byung Park,Scott Kelly,Nader Pourhassan,Alina Lelic,Lama Kdouh,Monica Herrera,Eric W. Hall,Benjamin N. Bimber,Matthew Plassmeyer,Raavi Gupta,Oral Alpan,Jane A. O’Halloran,Philip A. Mudd,Enver Akalin,Lishomwa C. Ndhlovu,Jonah B. Sacha +29 more
TL;DR: While the current study design precludes clinical efficacy inferences, these results implicate CCR5 as a therapeutic target for COVID-19 and form the basis for ongoing randomized clinical trials.
Posted ContentDOI
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
Bruce Pattterson,Harish Seetthamraju,Kush Dhody,Michael J. Corley,Kazem Kazempour,Jay Lalezari,Alina Pang,Christopher Sugai,Edgar B. Francisco,Amruta Pise,Hallison Rodrigues,Matthew Ryou,Helen L. Wu,Gabriela M. Webb,Byung Park,Scott Kelly,Nader Pourhassan,Alena Lelic,Lama Kdouh,Monica Herrera,Eric W. Hall,Enver Aklin,Lishomwa C. Ndhlovu,Jonah B. Sacha +23 more
TL;DR: A novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis is demonstrated and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19.
Journal ArticleDOI
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.
Kush Dhody,Nader Pourhassan,Kazem Kazempour,Derry Green,Shide Badri,Hana Mekonnen,Denis Burger,Paul J Maddon +7 more
TL;DR: Pro 140 has a potential to address an unmet need for a long- acting, single-agent, maintenance regimen for HIV infection in selected patients and has sufficient potency for a prolonged period of monotherapy that it would be an excellent component of a multi long-acting drug combination.
Journal ArticleDOI
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab
Nicholas Agresti,Jacob P. Lalezari,Phillip P. Amodeo,Kabir Mody,Steven F. Mosher,Harish Seethamraju,Scott Kelly,Nader Pourhassan,C. David Sudduth,Christopher Bovinet,Ahmed E. ElSharkawi,Bruce K. Patterson,Reejis Stephen,Jonah B. Sacha,Helen L. Wu,Seth A. Gross,Kush Dhody +16 more
TL;DR: It has been shown that in patients with severe COVID-19 treatment with leronlimab reduces elevated plasma IL-6 and chemokine ligand 5 (CCL5), and normalized CD4/CD8 ratios, which corresponds to restoration of the immune function as measured by CD4+/ CD8+ T cell ratio.
Journal ArticleDOI
Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.
Bryant Yang,Jonathan Fulcher,Jenny Ahn,Marlene Berro,David Goodman-Meza,Kush Dhody,Jonah B. Sacha,Arash Naeim,Otto O. Yang +8 more
TL;DR: The high recovery rate suggested benefit, and those with lower inflammatory markers had better outcomes, whereas some, but not all, patients appeared to have dramatic clinical responses, indicating that unknown factors may determine responsiveness to leronlimab.